[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634906":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":61,"collaborators":29,"id":63,"slug":29,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":29,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":29,"overallStatus":46,"whyStopped":29,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LY3537031","EXPERIMENTAL","LY3537031 administered subcutaneously (SC).",[13],"Drug: LY3537031",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo administered SC.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Administered SC.",[9],[26],"Brenipatide",{"type":22,"name":15,"description":23,"armGroupLabels":28,"otherNames":29},[15],null,[31],{"name":32,"affiliation":5,"role":33},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":41,"role":37,"phone":29,"phoneExt":29,"email":42},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Gastroenterology Health Partners Loc. 1","RECRUITING","Louisville","Kentucky","40218","United States",{"type":52,"coordinates":53},"Point",[54,55],-85.75941,38.25424,{"lat":55,"lon":54},[58],{"name":29,"role":37,"phone":59,"phoneExt":60,"email":29},"502-888-1988","11134",{"type":62,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100634906",false,"NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C","RENEW-IBS-C","Inclusion Criteria:\n\n* Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n\nExclusion Criteria:\n\n* Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality","ALL","18 Years","75 Years",{"count":74,"type":75},342,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[81,82],"Irritable Bowel Syndrome","Constipation","2026-05-11",{"date":85,"type":86},"2026-05-13","ACTUAL",{"date":88,"type":86},"2026-04-29",{"date":90,"type":75},"2027-09",{"name":5,"class":6},1]